Xenetic Biosciences Inc (XBIO) - Total Assets
Based on the latest financial reports, Xenetic Biosciences Inc (XBIO) holds total assets worth $5.07 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check XBIO capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Xenetic Biosciences Inc - Total Assets Trend (2011–2024)
This chart illustrates how Xenetic Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Xenetic Biosciences Inc to evaluate the quality of earnings relative to operating cash generation.
Xenetic Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Xenetic Biosciences Inc's total assets of $5.07 Million consist of 95.5% current assets and 4.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Xenetic Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Xenetic Biosciences Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xenetic Biosciences Inc's current assets represent 95.5% of total assets in 2024, an increase from 4.5% in 2011.
- Cash Position: Cash and equivalents constituted 89.3% of total assets in 2024, up from 4.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Xenetic Biosciences Inc Competitors by Total Assets
Key competitors of Xenetic Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Xenetic Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.56 | 6.96 | 13.20 |
| Quick Ratio | 4.56 | 6.96 | 13.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.96 Million | $6.02 Million | $11.43 Million |
Xenetic Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Xenetic Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.38 |
| Latest Market Cap to Assets Ratio | 0.72 |
| Asset Growth Rate (YoY) | -34.9% |
| Total Assets | $6.90 Million |
| Market Capitalization | $4.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xenetic Biosciences Inc's assets below their book value (0.72x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Xenetic Biosciences Inc's assets decreased by 34.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Xenetic Biosciences Inc (2011–2024)
The table below shows the annual total assets of Xenetic Biosciences Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.90 Million | -34.92% |
| 2023-12-31 | $10.61 Million | -27.96% |
| 2022-12-31 | $14.72 Million | -25.71% |
| 2021-12-31 | $19.82 Million | +50.35% |
| 2020-12-31 | $13.18 Million | -38.83% |
| 2019-12-31 | $21.55 Million | +49.31% |
| 2018-12-31 | $14.43 Million | -24.70% |
| 2017-12-31 | $19.16 Million | -8.63% |
| 2016-12-31 | $20.97 Million | +24.04% |
| 2015-12-31 | $16.91 Million | +3.63% |
| 2014-12-31 | $16.32 Million | -16.18% |
| 2013-12-31 | $19.47 Million | -23.28% |
| 2012-12-31 | $25.37 Million | +11302.81% |
| 2011-12-31 | $222.50K | -- |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, a… Read more